COVAX-19 is under clinical development by Vaxine and currently in Phase III for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase III drugs for Coronavirus Disease 2019 (COVID-19) have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how COVAX-19’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
COVAX-19 overview
COVAX-19 is under development for the treatment and prevention of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It comprises of delta inulin adjuvant. It is being developed based on Oracle Cloud technology and ADVAX technologies. It is administered through intramuscular and sublingual route. It acts by targeting coronavirus spike protein S. Spikogen/Covax-19 is a recombinant spike protein vaccine formulated with Advax-CpG55.2 adjuvant.
Vaxine overview
Vaxine is a biotechnology company that develops therapeutic vaccines for the treatment of infectious and chronic diseases. The company develops products for influenza vaccines, hepatitis B vaccines and Japanese encephalitis vaccines. It develops vaccines for seasonal and pandemic influenza, SARS, anthrax, Ebola, Marburg, ricin poisoning, flavivirus infection West Nile virus, malaria and rabies, among others. Vaxine also conducts intern program in vaccine research and development. The company partners with many universities, pharmaceuticals and biotechnology companies. Vaxine is headquartered in Adelaide, South Australia, Australia.
For a complete picture of COVAX-19’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
